Eir Drop



Eir Drop

Eir Drop

Table of Contents
Company Overview
We focus on the development of an innovative, scalable and patentable biotechnological platform based on Synthetic Biology to produce commercially viable biosynthetic cannabidiol for the global pharmaceutical market. A Biosystem made to provide an easier, economical and reliable way to obtain large amounts of high-value compounds.
Current Issues
Extraction and purification of biomolecules from its original source are complex and comes at high investment cost, slow cycles, no batch-to-batch consistency, toxic by-products and high carbon footprint. On the other hand, genetically engineered microorganisms can be used as mini-factories to produce the desired biomolecules. However, certain biomolecules are more complicated to biosynthesize than others. Inefficient conversion from input biomass and metabolic burdens control productivity flow rates, making biomanufacturing low and insufficient.
Our Solution
Cell-free Technology is a state-of-the-art technique that allows us to reproduce cellular biological transformations. It works by generating a cascade of molecular reactions allowing us to create a diverse range of proteins and biomolecules from inexpensive substrates, in a controlled environment, outside of the constraints of the living cell.
Should you invest?
The next revolution of CBD is recombinant, and its right here in Switzerland.
Allegory Capital Partners Tweet
Should you invest?
The next revolution of CBD is recombinant, and its right here in Switzerland.
Allegory Capital Partners Tweet